Galectin-3 Level in Ankylosing Spondylitis Patients

Recep Tayyip Erdogan University Training and Research Hospital

Status: Completed

Conditions: Ankylosing Spondylitis

Treatments: Other: Serum galectin-3 concentration was measured.

Study type: Observational

Funder types: Other

Identifiers

NCT04746196

2016/85

Details and patient eligibility

About

Forty-five AS patients and 35 healthy controls were enrolled in this study. Patients diagnosed with AS according to Modified New York criteria were included in the study. Clinical and laboratory measurements, duration of symptoms, age and body mass index (BMI) of AS patients were performed and compared with age and BMI matched control group.

Full description

Detailed histories of all participants were obtained, and systemic and rheumatologic examinations were performed. We excluded all participants who had a history of hyperlipidemia, liver, renal, hematological, familial thyroid, neoplastic, autoimmune infectious diseases and receiving anti-inflammatory drugs.

We measured serum galectin-3 levels using a commercial chemiluminescent microparticle immunoassay. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was used to assess disease activity in AS patients.

Enrollment: 80 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Ankylosing spondylitis patients
• Healthy controls

Exclusion criteria

• Hyperlipidemia
• Liver diseases
• Renal diseases
• Hematological diseases
• Familial thyroid diseases
• Neoplastic diseases
• Autoimmune infectious diseases
• Receiving anti-inflammatory drugs.

Trial design

80 participants in 2 patient groups

45 ankylosing spondylitis patients.

Description:

Patients diagnosed with ankylosing spondylitis according to Modified New York criteria were included in the study.

Treatment:

Other: Serum galectin-3 concentration was measured.

35 controls

Description:

Healthy controls

Treatment:

Other: Serum galectin-3 concentration was measured.